



Pharmaceutical equivalents’ consist of formulations with an identical active pharmaceutical ingredient (API), in the same molar amount and dosage form, 
which are intended to be used by the same route of 
administration. In addition, it is essential that the compared 
products fulfill quality  control standards, i.e.,  identity, 
API  content,  uniformity  of  dosage  units, dissolution 
performance, and  information  concerning storage (1, 
2). Another critical biopharmaceutical parameter  to 
be  considered  is  the  “dissolution stability”, because it 
is critical that the dissolution behavior of a formulation 
remain  unaffected  throughout its storage and use period 
(3).    
Furosemide (FURO), or 4-chloro-2-(2-furylmethylamino)-
5-sulfamoylbenzoic acid, is a loop diuretic, widely used 
by oral route for hypertension and edematous states 
treatment. This API presents an acidic nature, with a pKa 
value of 3.9, and an oral absorption mostly from gastric 
and upper small intestinal epithelium (4, 5). 
In the Biopharmaceutics Classification System (BCS), 
FURO is labeled as Class IV (6–9). When this class of API 
is formulated as immediate-release solid dosage form, 
intended to be administered by the oral route, it is 
expected to be subjected to bioequivalence studies. In fact, 
local legislation indicates that pharmaceutical products 
containing FURO should undergo a bioavailability/
bioequivalence (BA/BE) study (10). To the best of authors 
knowledge, there have been no studies about BA/BE of 
marketed products reported in the literature. 
However, it remains likely that in vitro studies can 
serve as a reliable indicator for potential problems with 
formulations containing Class IV APIs. Previous studies 
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comparing different FURO products were reported in the 
literature (11–15). Particularly in Argentina, Maggio et 
al. have studied eight batches of FURO tablets of three 
different brands, Ruiz et al. evaluated eleven brands, and 
Yong et al. assessed nine commercial samples (13–15). 
However, these studies focused on in vitro dissolution 
and mathematical considerations for dissolution profile 
comparison, without focus on evaluation of other critical 
quality attributes or assessment of pharmaceutical 
stability. 
The aim of this study was to compare critical quality 
characteristics, including in vitro dissolution performance, 
of FURO tablets (40 mg) from Argentina and to assess 
their pharmaceutical equivalence. The stability of the 
formulations was also considered to evaluate the effect 




FURO was obtained from Saporiti (Parafarm, Buenos 
Aires, Argentina). Distilled water and analytical grade 
sodium hydroxide (NaOH) and monobasic potassium 
phosphate (Anedra, Argentina) were used for preparation 
of assay solutions and dissolution medium.
Commercial Samples 
Eight different FURO (40 mg) tablets were purchased in 
the Argentine pharmaceutical market, and arbitrarily 
labeled as I–VIII. Sample III was identified as the 
reference, and the other formulations consisted in 
multisource products. Tablets identified as Sample VIII 
contained 50 mg of a different form of the API (FURO 
diethylaminoethanol), equivalent to 37 mg of FURO. All 
experiments were performed within the shelf life of the 
products. The composition of the evaluated formulations 
is presented in Table 1. 
Equipment 
The employed equipment include an analytical balance 
(ALC-210.4M, Acculab, Edgewood, NY, USA), a hardness 
tester (DGM02, Scout Electronics, Villa Ballester, 
Argentina), a friability tester (FGMO2, Scout Electronics), 
a disintegration tester (EGMO2, Scout Electronics), a 
dissolution equipment (DT60, Erweka, Heusenstamm, 
Germany), a ultraviolet (UV) spectrophotometer (Cary 
50 Conc, Varian Instruments, Mulgrave, Australia), and a 
stability climatic chamber (ICH 830 L, SCT Pharma, Vicente 
Lopez, Argentina).
Table 1. Excipients Composition 
Excipient Type Excipient
Sample
I II IIIb IVb V VIb VII VIII
Filler/Diluent
Lactose + + + + - + + +
Microcrystalline
+ - - - - - + -
Cellulosea
Disintegrant
Corn starcha - + + - + + - +
Povidonea - + - - + + + +
Crospovidone - - - + - - - -
Croscarmellose sodium - - - - - - + -
Docusate sodiuma - - - - - - + -
Sodium starch glycolate - + - - + - - -
Glidant
Sodium lauryl sulphatea - - - - - + -
Colloidal silicon dioxide + - + + + - + -
Talca - - + - + + + -
Lubricant Magnesium stearate + + + + + + + +
Coloring agent Ponceau 4R - - - - + - - -
 a Multiple functions have been described for this excipient. 
b The label (or leaflet) informs quantitative composition of excipients.
+ present; - absent 
32 NOVEMBER 2019
www.dissolutiontech.com
Quality Control Tests 
The information included in primary and secondary 
packaging (labels) and patient leaflets was evaluated and 
compared between samples to confirm compliance with 
Argentine regulations (16, 17).
Ten randomly chosen tablets of each formulation were 
independently weighed. The results for weight variation 
analysis were expressed as the mean value and its 
associated standard deviation (SD).
Argentine Pharmacopeia guidelines were followed to 
perform friability, hardness, and disintegration tests 
(16). Ten dosage units from each formulation, previously 
weighed, were placed into the tester for the determination 
of friability (i.e., the aptitude of tablets to resist erosion 
during mechanical processes such as packaging, 
handling, or shipping). The tablets were reweighed after 
100 revolutions (4 min at 25 rpm), and the result was 
compared with the value obtained before treatment (16). 
For hardness determination, 10 tablets of each sample 
were placed, one at a time, in the hardness tester, and 
enough force was applied to cause the fracture of the 
tablet across the diameter. The results were expressed 
in kilopounds (kip). Disintegration test was performed 
over six tablets of each sample, using distilled water at 
37.0 ± 2.0 °C as medium. The specification indicates that 
all tablets should fully disintegrate after 30 min, unless 
otherwise stated in the particular monograph (16).
Twenty tablets were weighed and finely ground for 
the assay test. A portion of the powder containing 
approximately 40 mg of FURO was exactly weighed and 
dissolved with 0.05 M NaOH. The prepared solution was 
filtered and suitably diluted with the same reagent, and 
the measurements were performed using a calibrated 
UV spectrophotometer at 271 nm (18). The standard 
calibration curve developed for the determination of 
FURO concentration was y = 60.651x – 0.0034 (r2 = 
0.9998), with a concentration range of 2.0–15.0 µg/mL. 
This assay method was individually applied over 10 tablets 
of each sample to test the uniformity of dosage units. 
For dissolution test , a United States Pharmacopeia (USP) 
apparatus 2 was used with 900 mL of phosphate buffer 
(pH 5.8) at 50 rpm (16). Six samples were evaluated at the 
first step of acceptance criteria (Stage 1, S1). The same 
conditions were applied for dissolution profiles, where at 
each sampling time (every 5 min during the first 15 min 
of the test, and every 15 min afterwards until the final 
sampling point of 60 min), 10-mL aliquots were extracted 
from the vessels and filtered (0.45-µm nylon membrane, 
Gamafil, Béccar, Argentina). After suitable dilution 
with the dissolution medium, FURO concentration was 
measured by spectrophotometric analysis (276 nm). The 
amount of FURO dissolved was calculated by the standard 
calibration curve constructed between concentrations of 
2.0 and 15.0 μg/mL (y = 60.545x + 0.0041, r2 = 0.9997). 
The results were compared with the pharmacopeial 
specification, which indicates that ‘not less than 70% (Q) 
of the labeled amount of FURO should dissolve within 45 
min’ (16).
Finally, dissolution profiles were also characterized 
in terms of dissolution efficiency (DE). This model-
independent parameter is defined as ‘the area under 
the dissolution curve up to a certain time, t, expressed 
as a percentage of the area of the rectangle described by 
100% dissolution in the same time’ (19). DE results were 
statistically compared using analysis of variance (ANOVA), 
at a level of probability p of 5 %. (Infostat, free version, 
Córdoba, Argentina). 
Storage conditions 
The formulations were stored for 12 months in their 
original packaging under ICH natural conditions for 
climatic zone II (25 °C, 60% R.H.) (20). Quality control tests 
were performed at time zero (T0) and after storage (T12). 
RESULTS AND DISCUSSION
Not all tablets containing 40 mg of FURO, available in the 
Argentine market at the date of this study, are considered 
equivalent with respect to the information provided 
about storage conditions (Table 2). It is considered that 
the correct indication would be to "preserve in well-
closed, inactinic (light-resistant) containers," which should 
be indicated both in the secondary packaging and in the 
leaflet (16). Products I, III, V, and VI did not mention the 
fact of light protection, and none of the samples indicated 
the requirement of tightly closed packaging. However, all 
samples referred to conditions of storage temperature, 
and almost all presented a superior limit of 30 °C (Table 2). 
FURO multisource products exhibited important 
differences in their price values, and the reference 
product showed the highest one, even duplicating the 
most economic available (Table 2). The sample price is a 
significant factor to consider because in Argentina there 
is an extensive use of multisource products, and patients 
make decisions about their interchangeability mostly 
based on economic considerations. 
The results of physical quality control tests are shown 
in Table 2. Large differences were detected between 
the weight values of samples, with mean values in the 
range of 118.4–253.1 mg. These variable results could 
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be explained based on differences in composition (as 
shown in Table 1), shape, and size of each pharmaceutical 
form, with no apparent correlation with fluctuations 
of the API content or dissolution performance. It can 
be seen in Table 2 that all evaluated samples complied 
with the specification for friability test, which states 
that ‘a maximum mean weight loss of not more than 
1.0% is considered acceptable’ (16, 21). With respect to 
hardness, the mean values were in the range of 4.8–8.4 
kip (Table 2). Although tablet breaking force is a general 
chapter in several pharmacopeias with no statement of 
specifications to be fulfilled, the obtained results were 
considered adequate. The specification for disintegration 
tests states ‘at the end of the time limit specified in the 
monograph, lift the basket from the fluid and observe the 
tablets: all of the tablets have disintegrated completely’ 
(16, 21). All tested products showed acceptable results, 
with values in the range of 20–536 s (0.3–8.9 min). 
Therefore, all samples met the specification for the 30-
min disintegration test (16, 21). 
The World Health Organization (WHO) recommends 
a strength of 40 mg for FURO oral dosage forms (22). 
All analyzed samples contain 40 mg of FURO, with the 
exception of formulation VIII. The latter states 50 mg of 
FURO diethylaminoethanol, which corresponds to 37 mg 
of FURO. However, its equivalence in FURO content is not 
indicated in the label nor the leaflet, which is confusing 
for patients and health professionals. In the other 
samples, with exception of product IV, there is a large 
and visible '40' in the secondary packaging. Moreover, no 
information about FURO diethylaminoethanol was found 
in the specialized literature or pharmacopoeias (16, 21).
Assay specification indicates that FURO tablets should 
contain 90.0–110.0% of the labeled amount (16, 21). 
Assay results (mean ±  SD) at T0 ranged between 91.1% 
± 2.9 (sample VIII) and 98.5% ± 1.1 (sample II), and results 
at T12 were between 94.4% ± 3.0 (sample VII) and 99.6% 
± 0.5 (sample V) (Table 3). These results indicate that all 
samples fulfilled assay specifications at both times of 
analysis. Statistical evaluation of these values indicated 
no significant differences detected between assay results 
at T0 and T12 for each individual sample. In addition, 
specifications for the uniformity of dosage unit test 
indicate that the API content in each single dosage unit 
should range between 85.0% and 115.0% of the labeled 
amount, and the relative standard deviation should be 
Table 2. Results of Quality Control Tests 




(% of weight loss)
Disintegration 
(s)c
I 1.28 Store in cool and dry room, at a temperature below 30 °C. 200.9 ± 4.0 6.6 ± 1.0 0.39 20
II 0.70 Store between 15 and 30 °C, protected from light. 200.7 ± 1.8 5.3 ± 0.3 0.69 218
III 1.83 Store at a temperature below 30 °C. 160.6 ± 1.8 5.2 ± 0.6 0.79 31
IV 1.34 Store in cool and dry room, protected from light. 253.1 ± 4.6 5.5 ± 2.2 0.64 64
V 0.94 Store at room temperature, between 15 and 30 °C. 213.4 ± 4.9 8.4 ± 1.4 0.12 108
VI 0.87 Store at room temperature, below 30 °C. 199.6 ± 1.8 7.4 ± 0.4 0.51 193
VII 1.04 Store in a cool and dry room, protected from light. 159.9 ± 1.9 4.8 ± 0.5 0.27 129
VIII 1.35 Store between 5 and 30 °C, protected from light. 118.4 ± 1.7 5.4 ± 0.3 0.25 536
 a Price per tablet at the time of analysis (Argentinian Pesos). 
b Information presented in labels and leaflets.
c Maximum time registered for complete disintegration. 
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lower than 6.0% (16, 21). All evaluated products fulfilled 
these requirements at T0 (Table 3). 
The Argentine Pharmacopoeia specification for in vitro 
dissolution testing of FURO tablets states that ‘not less 
than 70% (Q) of the labeled amount of FURO is dissolved 
in 45 minutes’ (16). All formulations complied with the 
specification for the Stage 1 dissolution test, both at T0 and 
T12, as shown in Table 3. The United States Pharmacopoeia 
is equivalent but differs in the specification, which 
indicates that ‘not less than 80% (Q) of the labeled amount 
of FURO is dissolved in 60 minutes’ (21). All samples also 
met this criterion (data not shown). Figures 1 and 2 show 
the dissolution profiles of the evaluated products at T0 
and T12, respectively. The dissolution profiles reach the 
plateau, both at T0 and T12, at 0–10 min for sample I, 10–
20 min for samples V and VII, and 30 min for samples II, III, 
IV, and VI. Sample VIII never reached the plateau and had 
poor dissolution performance. Statistical comparison of 
FURO dissolution profiles was performed in terms of DE. 
Mean DE values were in the range of 61.0–98.6% at T0, and 
61.1–96.1% at T12, with minimum and maximum values 
for samples VIII and I, respectively, in both conditions 
(Table 3). There were not significant differences between 
DE of the reference formulation (sample III) and samples 
II, IV, and VI; however, highly significant differences 
were recorded for samples I, V, VII, and VIII compared 
to the reference. Highly significant differences were also 
detected between samples I and VIII, with respect to the 
rest of the evaluated formulations. The same conclusions 
were achieved at T0 and T12. With respect to dissolution 
stability, only samples IV and VII showed highly significant 
changes after 12 months of storage under natural 
conditions. Nevertheless, they still fulfilled dissolution 
specifications at both times of analysis (Table 3). 
Table 3. Results of FURO Dissolution Tests
Sample





Specification: 90.0–110.0 % 85.0–115.0%; RSD < 6.0% 70% (Q) in 45 min.
I
T0 95.3 ± 4.7 [91.1–100.4] / 4.9 [101–109] / 2.5 98.6 ± 2.4
T12 98.3 ± 2.8 -- [98–105] / 3.2 96.1 ± 2.9
II
T0 98.5 ± 1.1 [97.3–99.3] / 1.1 [96–102] / 2.4 83.5 ± 4.8
T12 97.8 ± 1.5 -- [99–102] / 1.9 83.5 ± 3.7
III
T0 97.2 ± 2.0 [95.2–99.3] / 2.1 [89–103] / 4.6 81.7 ± 3.4
T12 98.4 ± 1.8 -- [100–102] / 1.1 83.9 ± 3.0
IV
T0 97.6 ± 2.3 [95.6–100.1] / 2.4 [90–99] / 3.0 83.3 ± 1.1
T12 95.2 ± 2.2 -- [90–94] / 2.3 80.3 ± 0.4
V
T0 97.2 ± 0.2 [97.0–97.4] / 0.2 [91–98] / 2.6 88.2 ± 2.1
T12 99.6 ± 0.5 -- [96–100] / 1.8 89.1 ± 2.9
VI
T0 96.7 ± 0.6 [96.2–97.3] / 0.6 [97–104] / 2.1 83.7 ± 2.8
T12 96.7 ± 1.2 -- [96–100] / 2.3 84.4 ± 3.5
VII
T0 96.0 ± 2.5 [93.1–97.9] / 2.6 [88–99] / 4.6 88.4 ± 2.4
T12 94.4 ± 3.0 -- [98–99] / 0.8 91.9 ± 1.2
VIII
T0 91.1 ± 2.9 [87.1–95.2] / 4.1 [80–95] / 6.5 61.0 ± 4.2
T12 96.3 ± 3.1 -- [86- 95] / 5.4 61.1 ± 3.2
a Results are mean percentage of labeled amount ± SD. 
b Results are [range of percentage of labeled amount]  / RSD. 
c Results are [range of percentage labeled amount dissolved] / RSD.
FURO, furosemide; Q,  amount of dissolved FURO, expressed as a percentage of the labeled content of the dosage unit, in the time specified in the 
dissolution test; S1, first stage of acceptance criteria for dissolution test ; T0, time zero; T12, time after 12 months storage; RSD: relative standard 
deviation; -- not applicable.
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Attending to the significantly lower dissolution 
performance of formulation VIII, this research further 
attempted to elucidate the reason for this behavior. Two 
new batches of the same formulation were evaluated, 
namely samples VIIIa and VIIIb. It is important to highlight 
that both samples VIIIa and VIIIb presented exactly the 
same qualitative excipient composition of the original 
sample VIII (Table 1). Table 4 shows the obtained results 
for these news batches at T0 and T12. Both batches 
fulfilled the specifications for assay, uniformity of dosage 
units, and dissolution test at both times of analysis; 
however, the dissolution profiles of VIIIa and VIIIb 
differed from VIII, with a considerably better dissolution 
performance compared to the original sample VIII (Fig. 
3). Highly significant differences were recorded between 
DE results of sample VIII with respect to VIIIa and VIIIb, 
both at T0 (61.0% versus 87.2% and 84.4%) and T12 (61.1% 
versus 83.3% and 80.1%). Additionally, samples VIIIa and 
VIIIb showed significant differences in DE results after 12 
months of storage compared to T0. Considering that the 
three samples (VIII, VIIIa and VIIIb) presented exactly the 
same excipient composition and that the poor dissolution 
performance of sample VIII was not repeated in the other 
samples of the same product, it can be concluded that 
this behavior was due to a particular batch problem. 
Although the dissolution performance of the new batches 
was statistically affected by aging, they still fulfilled 
pharmacopoeial specifications.
Figure 1. FURO dissolution profiles of samples I–VIII at time zero (T0). 
Data points are mean percentage of labeled amount dissolved at 
each sampling time with corresponding error bars (standard 
deviation). FURO, furosemide.
Figure 2. FURO dissolution profiles of samples I–VIII after 12 months 
of natural aging conditions storage (T12). Data points are mean 
percentage of labeled amount dissolved with corresponding error bars 
(standard deviation). FURO, furosemide. 
Sample
Time of Analysis Assaya Uniformity of Dosage Unitsb Dissolution Test (S1 Stage)c
Dissolution
Efficiencya
Specification: 90.0–110.0% 85.0–115.0%; RSD < 6.0% 70% (Q) in 45 min
VIIIa
T0 95.1 ± 0.8 [93.9–95.9] / 1.1 [97–104] / 3.3 87.2 ± 3.8
T12 93.9 ± 2.9 -- [96–100] / 2.0 83.3 ± 1.8
VIIIb
T0 97.7 ± 2.1 [93.0–99.2] / 1.4 [100–105] / 2.4 84.4 ± 2.3
T12 95.5 ± 1.0 -- [95–98] / 1.5 80.1 ± 1.9
Table 4. Results of FURO Dissolution Tests with New Batches of Sample VIII
a Results are mean percentage of labeled amount ± SD. 
b Results are [range of percentage of labeled amount]  / RSD. 
c Results are [range of percentage labeled amount dissolved] / RSD.
FURO, furosemide; Q,  amount of dissolved FURO, expressed as a percentage of the labeled content of the dosage unit, in the time specified in the 
dissolution test; S1,  first stage of acceptance criteria for dissolution test;  T0, time zero; T12, time after 12 months storage; RSD: relative standard 
deviation; -- not applicable.
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Figure 3.  FURO dissolution profiles of samples VIII, VIIIa, and VIIIb at time 
zero (T0) and after storage (T12). Data points are mean percentage of 
labeled amount dissolved with corresponding error bars (standard 
deviation). FURO, furosemide.
CONCLUSION
The evaluated samples were considered pharmaceutical 
equivalents under the experimental conditions 
employed. Despite some statistical differences detected 
in the dissolution profiles, all evaluated products fulfilled 
pharmacopeial specifications and passed the quality 
control tests after 12 months of storage. One of the 
evaluated formulations showed a very low dissolution 
performance, but it was later confirmed that it 
corresponded to a particular batch problem. Our results 
demonstrate that FURO products available in the local 
market are stable pharmaceutical equivalents.
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Powerful standalone solutions. 
Or a fully integrated automated 
system for high efficiency.
It’s “The German Gründlichkeit”.
The PTWS 820D is a compact fully USP/EP 8-position tablet dissolution testing instrument. 
Ideal for dissolution profiling with additional check of the blank and reference media. 
The PTWS 820D is also available as the online automated tablet dissolution testing system 
ADS-L 820 for a »closed loop« with automated sampling, measuring and result calculation. 
The ADS-L 820 includes a TIDAS® L diode array spectrometer from our sister company J&M 
with an integrated PC running the user-friendly, highly advanced and versatile Pharma Test 
WinDiss ARGUS software. The software is not only fully 21 CFR Part 11 compliant, data integ-
rity is also ensured. All instruments are fully USP/EP/CP/JP/USFDA/ASTM compliant. 
Automated and integrated effectiveness or standalone powerhouses 
